20-F: Check-Cap Pivots to AI & Ghost Kitchens, Reports 2025 Net Income

Check-Cap Ltd. reports a net income of $4.1 million for 2025, driven by a strategic pivot to AI and Ghost Kitchens through a merger with MBody AI and a debt-for-equity exchange with Apollo.

Summary

• Check-Cap Ltd. is undergoing a significant strategic transformation, pivoting from its historical medical diagnostics business (C-Scan) to artificial intelligence and ghost kitchen operations.
• The company reported a net income of $4.1 million for the year ended December 31, 2025, a substantial improvement from net losses of $25.1 million in 2024 and $17.6 million in 2023.
• This net income was primarily driven by a non-cash credit loss recovery of $6.5 million related to the reinstatement of a loan receivable from Apollo Technology Capital Corporation.
• The core of the strategic pivot is the pending merger with MBody AI Inc., an AI technology company specializing in robotic and software systems for large commercial environments, approved by shareholders on November 14, 2025, and expected to close in the first half of 2026.
• Upon merger closing, former MBody AI equityholders are expected to own approximately 90% of the combined company, and former Check-Cap equityholders approximately 10%. The company will be renamed MBody AI Ltd.
• Check-Cap's outstanding loans to Apollo, totaling approximately $16.3 million, were converted into a 7.5% equity position in Apollo, valued at $6.5 million, contingent on the merger closing.
• The company also acquired exclusive Ghost Kitchen area representative rights in New Jersey on September 4, 2025, issuing 1,169,596 ordinary shares as consideration.
• Check-Cap entered into a Purchase Agreement with ARC Group International Ltd. on December 17, 2025, for an equity line of credit (ARC ELOC Facility) of up to $30.0 million over three years.
• The company has a history of losses, with an accumulated deficit of $165.9 million as of December 31, 2025, and management has identified substantial doubt about its ability to continue as a going concern.
• Research and development expenses for the legacy C-Scan technology were $0 in 2025 and 2024, down from $8.3 million in 2023, reflecting the discontinuation of those activities.
• General and administrative expenses decreased to $2.4 million in 2025 from $9.5 million in 2024.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development given the company's successful pivot from a struggling legacy business to new, potentially high-growth sectors like AI and ghost kitchens, backed by a significant capital raise facility and a return to net income. However, the substantial dilution for existing shareholders, the 'going concern' doubt, and the inherent risks of MBody AI's limited operating history temper the overall sentiment.

Positives

• Achieved a net income of $4.1 million in 2025, a significant turnaround from previous years' losses.
• Successful shareholder approval (98.01%) for the merger with MBody AI, indicating strong investor support for the strategic pivot.
• Secured an equity line of credit (ARC ELOC Facility) for up to $30.0 million, providing a potential source of future capital.
• Acquisition of Ghost Kitchen franchise rights in New Jersey offers a new, near-term revenue-generating opportunity.
• Conversion of $16.3 million in Apollo loans into a 7.5% equity stake in Apollo, which was reinstated at a value of $6.5 million after initial impairment.
• MBody AI's business model emphasizes recurring, higher-margin software-as-a-service (SaaS) and AI-platform subscriptions.
• MBody AI's AI Orchestrator platform is hardware-agnostic, allowing integration with diverse robotic systems.
• Reduction in general and administrative expenses by $7.1 million in 2025 compared to 2024.

Negatives

• Despite net income, operating cash flows remain negative, and the company has an accumulated deficit of $165.9 million as of December 31, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern.
• The merger with MBody AI is subject to various conditions and uncertainties, with no assurance of timely completion or at all.
• Existing Check-Cap shareholders will experience significant dilution, owning only approximately 10% of the combined company post-merger.
• MBody AI has a limited operating history and a history of operating losses since inception, making its future prospects difficult to evaluate.
• MBody AI relies on a limited number of customers and third-party vendors, posing concentration and supply chain risks.
• The company's historical C-Scan medical diagnostics business has been discontinued due to efficacy results not meeting study goals and high development costs.
• Ongoing legal proceedings, including a shareholder derivative lawsuit and claims from former executives and a legal services provider.
• The company ceased making rent payments for its Isfiya premises, leading to an eviction order and property remaining on site.
• The equity interest in Apollo is illiquid, a minority stake, and has no governance rights, with uncertain fair value realization.
• Potential for significant dilution from future sales under the ARC ELOC Facility.
• The company may be classified as a Passive Foreign Investment Company (PFIC), leading to adverse U.S. federal income tax consequences for U.S. investors.
• The company's principal offices and operations are in Israel, exposing it to political, economic, and military instability risks.

Risks

• The issuance of ordinary shares in connection with the Merger will substantially dilute the relative voting power of holders of Check-Cap ordinary shares prior to the closing of the Merger, and, as a result, such holders will exercise substantially less influence over the management and policies of the combined company following the consummation of the Merger.
• The Company has incurred and expects to continue to incur substantial non-recurring transaction-related costs in connection with the Merger, including legal, accounting, regulatory filing, and other professional fees, which will be incurred regardless of whether the Merger is completed.
• The Company may fail to realize the anticipated benefits of the Merger, including as a result of difficulties in integrating the operations and personnel of the two companies, failure to retain key employees, higher-than-expected integration or transaction costs, and unforeseen market or economic conditions.
• The Company may become involved in securities class action litigation or shareholder derivative litigation in connection with the Merger, which could result in substantial costs, divert management's attention and resources, and have a material adverse effect on the Company's business, financial condition, and results of operations.
• If the Merger is not completed for any reason, the Company will need to evaluate its strategic alternatives and will require significant additional funding in order to continue operations, and if such funding is not available on acceptable terms, the Company may be forced to significantly curtail or cease operations.
• The Apollo BCA remains in effect and will not terminate unless and until the Merger closes, and the Company has outstanding other payables due to Apollo in the aggregate principal amount of approximately $1.4 million as of December 31, 2025, the conversion of which to equity in Apollo is contingent on the closing of the Merger.
• The Company has a history of losses, may incur future losses and require additional funding in order to complete the development of its products and technology. If additional capital is not available and the Company ceases the development of its products and technology or is obligated to relinquish rights to its intellectual property, the Company may not ever achieve profitability and be forced to liquidate.
• The Company may not recover amounts loaned to Apollo, and any equity interest in Apollo the Company ultimately holds may be illiquid and of uncertain value.
• Management and board of directors have concluded that a substantial doubt is deemed to exist concerning the Company's ability to continue as a going concern.
• MBody AI has a limited operating history and an evolving business model, which makes it difficult to evaluate its future prospects and may adversely affect MBody AI's ability to achieve its business objectives.
• MBody AI currently relies on a limited number of customers, and the loss or reduction of business from any customer could materially adversely affect its results of operations.
• MBody AI's operations depend on a small number of third-party vendors, deployment partners, and hardware suppliers, and any failure by its suppliers to deliver on schedule, in sufficient quantities, or at anticipated price points could delay customer implementations or impair revenue targets.
• MBody AI operates in regulated environments, including hospitality, gaming, and potentially healthcare, and regulatory requirements may change over time, differ by jurisdiction, or impose additional compliance costs that could adversely affect its ability to deploy its platform or expand into new markets.
• MBody AI may face liability or compliance exposure related to the operation of autonomous systems, and the evolving regulatory landscape for artificial intelligence, robotics, and autonomous systems could impose additional obligations or restrict certain applications.
• MBody AI has a history of operating losses since inception and may not achieve or sustain profitability, and will require additional capital to execute its business plan, which may not be available on acceptable terms.
• MBody AI operates in a rapidly evolving and competitive market, and new technologies, business models, or competitors may emerge that could reduce demand for its platform or render its offerings less competitive.
• MBody AI's success depends on its ability to attract and retain key management and technical personnel, and the loss of key personnel or inability to attract additional talent could materially adversely affect its business.
• It is not possible to predict the actual number of shares the Company will sell under the Purchase Agreement with ARC Group International Ltd. (the ARC ELOC Facility), or the actual gross proceeds resulting from those sales, and the total proceeds could be substantially less than the $30.0 million total commitment amount.
• The Company may require additional financing to sustain its operations beyond the Purchase Agreement, and such financing may not be available on acceptable terms, or at all, which could materially adversely affect its business, financial condition, and results of operations.
• Future sales and issuances of the Company's ordinary shares, including pursuant to the Purchase Agreement, might result in significant dilution to existing shareholders and could cause the price of the Company's ordinary shares to decline.
• The Company undertakes to seek shareholder approval to re-designate its ordinary shares as no-par value, and any delay or failure to complete the re-designation could limit its flexibility to issue shares under the Purchase Agreement and adversely affect its ability to raise capital.
• There can be no assurance that the Company will realize the anticipated benefits of the acquisition of Ghost Kitchen franchise rights in New Jersey, including generating revenue from the acquired operations.
• The Company issued 1,169,596 ordinary shares as consideration for the acquisition of Ghost Kitchen franchise rights in New Jersey, and while the shares are subject to a two-year lock-up period and a voting agreement, the eventual availability of those shares for resale in the public market could adversely affect the price of the Company's ordinary shares.
• Although the Company received Food and Drug Administration (FDA) approval of its investigational device exemption (IDE) for its U.S. pivotal study, the most recent efficacy results from its studies did not meet the goal to proceed to the powered portion of the U.S. pivotal study, as such the Company cannot provide any assurance that it will ever be able to redesign such study or redeploy its technology into other potentially viable products.
• Clinical failure can occur at any stage of clinical development, and the Company may not succeed in completing the development of its product. Any product the Company advances through clinical trials may require further clinical validation and may not have favorable results in later clinical trials or receive regulatory approval.
• The Company may face a number of challenges with respect to its commercialization efforts and may not succeed in the commercialization of its product, obtain required regulatory approvals or manufacture commercial quantities of C-Scan at an acceptable cost to enable it to generate significant revenues.
• The Company has limited manufacturing experience and capabilities and if it is unable to scale up its manufacturing operations to develop its products, its growth could be limited and its business, financial condition and results of operations could be materially adversely affected.
• The Company's reliance on sole or single source suppliers could harm its ability to conduct clinical trials and meet demand for its product in a timely manner or within its budget.
• The use of any of the Company's C-Scan Cap, C-Scan Track, C-Scan View or any new products and technology could result in product liability or similar claims that could be expensive to defend, damage its reputation and harm its business.
• The Company has historically depended on third parties to manage its clinical studies and trials, perform related data collection and analysis, and to enroll patients for its clinical trials, and, as a result, it may face costs and delays that are beyond its control.
• The Company may sell its products in the United States, Europe, Israel and Japan and, if it is unable to manage its operations in these territories, its business, financial condition and results of operations could be materially adversely affected.
• The Company may not be successful in establishing and maintaining strategic partnerships, which could adversely affect its ability to develop and commercialize its products and technology.
• A security breach or disruption or failure in a computer or communications systems could adversely affect the Company.
• The Company or the third parties upon whom it depends may be adversely affected by natural disasters and/or health epidemics or pandemics and/or war and conflicts and its business continuity and disaster recovery plans may not adequately protect it from a serious disaster.
• Shareholder activism could result in potential operational disruption, divert the Company's resources and management's attention and have an adverse effect on its business.
• If the Company or its future manufacturers or distributors do not obtain and maintain the necessary regulatory clearances or approvals, or equivalent third country approvals in a specific country or region, the Company or its future distributors will not be able to market and sell C-Scan or future products in that country or region.
• If the indications for use or instructions for use for which the iodinated oral contrast medium is approved are not sufficiently broad to support its use throughout the C-Scan procedure, the FDA or the competent regulatory authorities in the European Union (EU) Member States and other foreign countries may consider that contrast agent is being used off-label.
• The results of any future clinical trials may not support the Company's product candidate requirements or intended use claims or may result in the discovery of adverse side effects.
• Even if C-Scan or future products are cleared or approved by regulatory authorities or after obtaining CE Certificates from a notified body, modifications to C-Scan or future products may require new regulatory clearances or approvals, new CE Certificates, or may require the Company to recall or cease marketing it until the necessary clearances, approvals or CE Certificates are obtained.
• The Company's failure to comply with radiation safety or radio frequency regulations in a specific country or region could impair its ability to conduct its clinical trials, or commercially distribute and market C-Scan or any similar product in that country or region.
• The Company's products may in the future be subject to product recalls that could harm its reputation, business and financial results.
• If C-Scan or future products cause or contribute to a death or a serious injury, or malfunction in such a way that causes or contributes to a death or serious injury, the Company will be subject to medical device reporting regulations, which can result in corrective actions or enforcement actions from regulatory authorities.
• The Company's business is subject to complex environmental and health legislation in various jurisdictions that may increase its costs and its risk of noncompliance.
• Federal and state privacy laws, and equivalent laws of third countries, may increase the Company's costs of operation and expose it to civil and criminal sanctions.
• If the Company fails to comply with the U.S. federal Anti-Kickback Statute and similar state and third-country laws, it could be subject to criminal and civil penalties and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third-country programs, which would have a material adverse effect on its business and results of operations.
• The Company's failure to comply with the necessary regulatory approval regarding the use of radioactive materials could significantly impair its ability to develop, manufacture and/or sell C-Scan or similar products.
• The Company's ability to source and distribute its products profitably or at all could be harmed if new trade restrictions are imposed or existing trade restrictions become more burdensome.
• If the Company is unable to protect its intellectual property rights, its competitive position could be harmed.
• Because the medical device industry is litigious, the Company is susceptible to intellectual property suits that could cause it to incur substantial costs or pay substantial damages or prohibit it from selling C-Scan or any similar products it may develop.
• The steps the Company has taken to protect its intellectual property may not be adequate, which could have a material adverse effect on its ability to compete in the market.
• Third parties may challenge the validity of the Company's issued patents or challenge patent applications in administrative proceedings before various patent offices which, if successful, could negatively affect its future business and financial performance.
• The Company may need to initiate lawsuits to protect or enforce its patents and other intellectual property rights, which could be expensive and, if it loses, could cause it to lose some of its intellectual property rights, which would harm its ability to compete in the market.
• The Company relies on trademark protection to distinguish its products from the products of its competitors; however, if a third party is entitled to use its trademark, the Company could be forced to rebrand, which could result in loss of brand recognition and its ability to distinguish its products may be impaired, which could adversely affect its business.
• The Company may not be able to enforce covenants not to compete at all or, it may be unable to enforce them for the duration contemplated in its employment contracts and may, therefore, be unable to prevent competitors from benefiting from the expertise of some of its former employees involved in research and development activities.
• The Company's principal offices, research and development facilities, its manufacturing sites and some of its suppliers are located in Israel and, therefore, its business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel.
• Pursuant to the terms of the Israeli government grants the Company received for research and development expenditures related to its historical business, it is obligated to pay certain royalties on its revenues from its legacy products to the Israeli government. In addition, the terms of an Israeli government grant the Company received require it to satisfy specified conditions and to make additional payments in addition to repayment of the grants upon certain events.
• Shareholder rights and responsibilities are governed by Israeli law, which differ in some material respects from the rights and responsibilities of shareholders of U.S. companies.
• It may be difficult to enforce a judgment of a U.S. court against the Company, certain of its officers and directors or the Israeli experts named in this Annual Report in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on certain of its officers and directors and these experts.
• Provisions of Israeli law and the Company's amended articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, the Company, even when the terms of such a transaction are favorable to the Company and its shareholders.
• The Company may become subject to claims for payment of compensation for assigned service inventions by its current or former employees relating to its historical business, which could result in litigation and adversely affect its business.
• The Company incurs and will continue to incur significant costs as a result of operating as a public company in the United States, and its management is required to devote substantial time to compliance initiatives.
• If the Company fails to maintain effective internal control over financial reporting, the price of its ordinary shares may be adversely affected.
• The Company may be unable to maintain compliance with Nasdaq's continued listing requirements, which could result in the delisting of its ordinary shares from the Nasdaq Capital Market.
• As a foreign private issuer, the Company is not subject to U.S. proxy rules and is subject to the Securities Exchange Act of 1934 reporting obligations that, to some extent, are more lenient and less frequent than those applicable to a U.S. issuer.
• As a foreign private issuer, the Company is permitted to follow, and follows certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.
• If the Company loses its status as a foreign private issuer under the SEC's rules, its compliance costs will increase.
• Exchange rate fluctuations between the U.S. dollar and the NIS and the Euro and inflation may negatively affect the Company's earnings and it may not be able to hedge its currency exchange risks successfully.
• The Company has never declared or paid a dividend and currently does not intend to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of its securities.
• If securities or industry analysts do not publish research or reports about the Company or its business or publish unfavorable research about the Company or its business, the price of its securities and their trading volume could decline.
• The Company's stock price has and may be subject to fluctuation, and purchasers of its securities could incur substantial losses.
• The trading market for the Company's ordinary shares is not always active, liquid and orderly, which may inhibit the ability of its shareholders to sell ordinary shares.
• The Company has broad discretion in how it uses the net proceeds from its financings, and it may not use these proceeds effectively.
• The Company's business, operating results and growth rates may be adversely affected by current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.
• There is a risk that the Company could be treated as a domestic (U.S.) corporation for U.S. federal income tax purposes by reason of the transactions related to its acquisition of all of the business operations and substantially all of the assets of Check-Cap LLC on May 31, 2009 (the Reorganization).
• The Company may be eligible for tax benefits from government programs relating to its historical assets, which require it to meet certain conditions, including regarding the location of its property, plant and equipment and manufacturing in Israel. The Company can provide no assurance that it would continue to be eligible for such benefits and/or that any such benefits will not be terminated in the future.
• There is a risk that the Company may be classified as a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences to U.S. investors.

Future Outlook

The Merger with MBody AI is expected to consummate in the first half of 2026, transforming Check-Cap into MBody AI Ltd., a Nasdaq-listed embodied-AI enterprise. The combined company's principal operations will be MBody AI's business, with Check-Cap's legacy R&D activities continuing and legacy assets (patents, medical equipment) maintained. The Ghost Kitchen franchise rights are expected to complement and create potential synergies with the combined company. The company expects to require additional financing to fund its operations, growth initiatives, and platform development. Management plans to address going concern doubt primarily through the pending Merger and the ARC ELOC Facility. The company does not anticipate generating significant revenue from product sales for the foreseeable future and expects to continue to incur losses from operations for the foreseeable future.

Management Comments

• Management's plans to address these conditions [going concern] principally the pending Merger and the ARC ELOC Facility depend on external approvals and market conditions outside our sole control and are not, under ASC 205-40, probable of alleviating that doubt.
• We believe the claims in the derivative action are without merit and we intend to defend vigorously against this action.
• For all of the above matters [legal proceedings], based on the information currently available and after consultation with legal counsel, management does not believe an unfavorable outcome is probable and, accordingly, no provision has been recorded in these consolidated financial statements as of December 31, 2025.

Industry Context

StockSavvy.ai notes that Check-Cap's strategic pivot from medical diagnostics to AI-enabled robotics and ghost kitchens reflects a broader trend of companies seeking new growth avenues and leveraging emerging technologies, especially when core legacy businesses face significant development hurdles and high cash burn. The move into AI and automation aligns with increasing enterprise demand for operational efficiency, while the Ghost Kitchen acquisition taps into the growing food delivery market. This diversification strategy, while potentially high-reward, also introduces new operational complexities and competitive landscapes for a company with a limited history in these new sectors.

Comparison to Industry Standards

• MBody AI operates in rapidly evolving and highly competitive markets for artificial intelligence, automation, and autonomous systems, facing competition from companies developing and deploying robotics and autonomous systems, as well as other technology companies offering enterprise automation solutions.
• For the legacy C-Scan business, competition came from traditional manufacturers of CRC screening tests and equipment such as Olympus, Pentax, Hoya, Fuji Film (colonoscopy/sigmoidoscopy), GE Healthcare, Siemens, Philips, Toshiba (CTC), Medtronic plc (optical capsule endoscopy), and non-invasive technologies from Exact Sciences, Polymedco, Epigenomics AG, Gene News, EDP Biotech Corporation, Illumina, Inc., Quest Diagnostics, VolitionRx Nu.Q diagnostic, Freenome, Grail, Guardant, Genoscopy and Universal DX.
• C-Scan's average calculated radiation exposure of 0.05 mSv is significantly lower than CT colonography (approximately 6.0 mSv) and comparable to a single chest X-ray (approximately 0.06 mSv).
• In a post-CE approval study, C-Scan achieved a sensitivity of 76% in patients with polyps ≥10mm, outperforming FIT which achieved 29% sensitivity for the same. C-Scan achieved a specificity of 82%, while FIT achieved 96%.
• CMS criteria for blood-based CRC screening tests require both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of CRC compared to colonoscopy. C-Scan's reported sensitivity of 76% for polyps ≥10mm meets the sensitivity threshold, but its specificity of 82% is below the 90% threshold.

Management Changes

Corporate Governance

Legal Proceedings

• A minority shareholder filed a derivative lawsuit on October 7, 2024, in the Haifa District Court, seeking damages exceeding NIS 2.5 million (approximately $784,000) against the company, certain present and former directors, and a third party, primarily related to corporate governance matters and the legality of certain corporate transactions. The parties are currently engaged in mediation.
• Two former senior executives filed separate claims during 2024, seeking an aggregate of approximately NIS 620,000 (approximately $195,000) for alleged unpaid compensation and contractual entitlements following the termination of their engagements.
• A former legal services provider filed a claim during 2024, seeking approximately NIS 175,000 (approximately $55,000) for alleged unpaid legal fees. The parties are engaged in mediation proceedings.
• The company ceased making rent payments for its leased premises in Usfiyeh, Israel, in September 2024, leading to legal proceedings and an eviction order. The landlord's claim for unpaid rent and damages totals approximately NIS 207,000 (approximately $65,000).

Related Party Transactions

• Loans to Apollo Technology Capital Corporation: Check-Cap provided approximately $16.3 million in loans to Apollo, which were converted into a 7.5% equity position in Apollo, valued at $6.5 million, contingent on the merger closing. A payable of $1.4 million to Apollo remains as of December 31, 2025.
• Issuance of shares to Parea LLC: 1,169,596 ordinary shares were issued to Parea LLC as consideration for the acquisition of Ghost Kitchen area representative rights in New Jersey.
• Issuance of shares to ARC Group International Ltd.: 267,857 ordinary shares were issued as a commitment fee for the ARC ELOC Facility.
• Compensation to non-executive directors: $109,000 in fees and expenses in 2025.
• Consulting fees to Sigalit Kimchy (wife of former CTO Yoav Kimchy): $188,000 in 2025, including share-based compensation and reimbursement of expenses.
• Reimbursement liability to Check-Cap LLC unitholders: $0 as of December 31, 2025, as no profitability is expected, related to tax burdens from the 2009 reorganization.

Stakeholder Impact

• Shareholders (existing Check-Cap): Will experience significant dilution, with expected ownership of approximately 10% of the combined company post-merger. Potential for stock price volatility and uncertainty regarding the value of the illiquid Apollo equity investment. Future dilution from the ARC ELOC Facility is also a risk.
• Shareholders (MBody AI): Will become the majority owners (expected 90%) of the combined company, gaining access to a Nasdaq listing and the benefits of a public market.
• Employees: The legacy C-Scan business saw a significant workforce reduction in June 2023. New opportunities and integration challenges are expected with the MBody AI merger.
• Customers (MBody AI): Potential for enhanced offerings, broader market reach, and increased stability from being part of a larger, publicly traded entity.
• Customers (Ghost Kitchens): Expansion of franchise opportunities in New Jersey through the acquired area representative rights.
• Creditors (Apollo): Loans converted to an equity stake, contingent on the merger closing, with the value of this equity being uncertain and illiquid.
• Israeli Government (IIA/BIRD Foundation): Contingent royalty obligations for past R&D grants remain, but are not anticipated to be payable in the foreseeable future due to the discontinuation of legacy product development and lack of revenue from those products.

Next Steps

• Consummate the merger with MBody AI Inc. in the first half of 2026.
• Change the company name to MBody AI Ltd. or a similar name approved by the Israeli Registrar of Companies.
• Integrate MBody AI's business and operations as the principal activities of the combined company.
• Continue Check-Cap's legacy research and development activities and maintain legacy assets, primarily patents and proprietary medical equipment.
• Manage and expand the Ghost Kitchen area representative business in New Jersey to generate revenue.
• Utilize the ARC ELOC Facility for capital as needed to fund operations and growth initiatives.
• Seek shareholder approval to re-designate ordinary shares as no-par value to enhance flexibility in issuing shares.
• Address ongoing legal proceedings, including the shareholder derivative lawsuit and claims from former executives and a legal services provider.
• Monitor and respond to evolving regulatory landscapes for artificial intelligence, robotics, and autonomous systems.

Key Dates

Recommendation

The company is undergoing a significant and complex transformation, pivoting from a discontinued medical diagnostics business to AI-enabled robotics and ghost kitchens. While the reported net income and new capital raise facility are positive, the substantial dilution for existing shareholders, the 'going concern' doubt, and the inherent risks associated with MBody AI's limited operating history and competitive markets warrant caution. A 'Hold' recommendation is appropriate as investors should monitor the successful integration of MBody AI, the realization of anticipated synergies, and the company's ability to achieve sustainable profitability in its new ventures before considering further investment.

Keywords

MBody AI, Check-Cap, Merger, AI Orchestrator, Robotics, Artificial Intelligence, Ghost Kitchens, SEC Filing, Annual Report, Form 20-F, Nasdaq, Equity Line of Credit, Debt-for-Equity Exchange, Medical Diagnostics, C-Scan, Colorectal Cancer Screening, Israel, Corporate Governance, Financial Results